title: Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
abstract: Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life. The present study aims to elicit patient preferences with respect to the attributes of treatments for metastatic prostate cancer through a discrete choice experiment (DCE) questionnaire. Men with recently diagnosed localized prostate cancer were asked to envisage that they had metastatic disease when completing a survey. As expected, men with prostate cancer placed considerable importance on gains in survival; however, avoiding side effects of treatment was also clearly important. Survival gains should be considered alongside side effects when discussing treatment options in metastatic disease.
authors.affiliation: Center for Health Outcomes Research, United BioSource Corporation, 20 Bloomsbury Square, London, WC1A 2NS, UK. andrew.lloyd@unitedbiosource.com
authors.forename: A
authors.initials: A
authors.lastname: Lloyd
authors.forename: D
authors.initials: D
authors.lastname: Penson
authors.forename: S
authors.initials: S
authors.lastname: Dewilde
authors.forename: L
authors.initials: L
authors.lastname: Kleinman
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000191:economics / Q000523:psychology / Q000556:secondary*; D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000813:Anilides / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002755:Choice Behavior; D003430:Cross-Sectional Studies; D003967:Diarrhea / Q000139:chemically induced / Q000523:psychology; D004334:Drug Administration Schedule; D016527:Drug Costs; D004358:Drug Therapy / Q000523:psychology; D007172:Erectile Dysfunction / Q000139:chemically induced / Q000523:psychology; D005485:Flutamide / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006177:Gynecomastia / Q000139:chemically induced / Q000523:psychology; D006306:Health Surveys; D006417:Hematuria / Q000139:chemically induced / Q000523:psychology; D006801:Humans; D008017:Life Expectancy; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D010342:Patient Acceptance of Health Care; D017060:Patient Satisfaction; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000523:psychology; D014105:Tosyl Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014105:Tosyl Compounds; D005485:Flutamide; C053541:bicalutamide